

OncoGenex Pharmaceuticals Inc

Presenting Company

Clinical Foci: Oncology • Biopharmaceuticals



Scott Cormack

Chief Executive Officer

1522 217th Place SE, Suite 100
Bothell, WA 98021
USA

www.oncogenex.com

1-604-736-3678

NASDAQ Stock Market: **OGXI**

Incorporated: 2000

Employees: 27

Ownership: Public

HIGHLIGHTS

Recent

Initiated two separate Phase III trials of custirsen in advanced castrate resistant prostate cancer
Initiated randomized phase 2 trial of OGX-427 in prostate cancer.
Completed approximately \$50M financing in late 2010 to fund operations to mid-2014.

Upcoming

Initiate Phase III trial of custirsen (OGX-011) in non-small cell lung cancer in 2011.
Initiate randomized phase 2 trial of OGX-427 in bladder cancer in 2011.

CORPORATE MISSION

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. Each product candidate in OncoGenex's oncology pipeline has a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceuticals Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 has entered Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

CORPORATE ALLIANCES

Teva Pharmaceuticals for development and commercialization of custirsen (OGX-011)

PRODUCTS


Name	Indication	Phase	Milestone
custirsen (OGX-011)	Castrate resistant prostate cancer, non-small cell lung cancer	Phase III	Both Phase III trials in CRPC were initiated in 2010; initiate Phase III trial in NSCLC in 2011
OGX-427	Castrate resistant prostate cancer, bladder cancer	Phase II, IIa, IIb	Randomized Phase II trial in prostate cancer was initiated in 2010; Randomized phase 2 in bladder cancer to be initiated in 2011.
SN2310	Solid tumors	Phase I	out-licensing opportunities
CSP-9222	Various treatment resistant tumors	Preclinical	
OGX-225	IGF-1 dependent cancers	Preclinical	

SENIOR MANAGEMENT

Scott Cormack, Chief Executive Officer • **Michelle Burris**, Chief Financial Officer • **Cindy Jacobs, PhD, MD**, Chief Medical Officer

BOARD OF DIRECTORS

Jack Goldstein, PhD, former president and Chief Operating Officer of Chiron • **David Smith**, executive vice president and chief financial officer of Thoratec Corporation • **Neil James Clendeninn PhD, MD**, former Corporate Vice President, Head of Clinical Affairs of Agouron Pharmaceuticals • **Martin Mattingly**, Chief Executive Officer and member of the board of directors of Trimeris • **Stewart Parker**, former president, Chief Executive Officer of Targeted Genetics • **Scott Cormack**, president and CEO of OncoGenex



Market Data

Current Price	16.92
Currency	US Dollar
Net Change	-2.25
Volume	27,466
YTD % Change	0.01
52Wk Range	11.83–22.71
Avg. Daily Volume (thousands).....	71,251

First Call Data

Market Cap (MM)	163.4
Short Interest Shares	80,824
Short Interest Ratio	2.44
PE (Trailing 12 Months)	-1.88
EPS (Last Fiscal Year)	-0.83
Consensus Estimate (Y)	-1.88
Consensus Recommend	-1.59
Price/Sales	2.98

Shareholders

<i>Institution</i>	<i>Holding %</i>
Bascom Hill Partners LLC	2.2%
First Eagle Investment Management LLC	1.5%
BlackRock Fund Advisors	1.3%
ING Investment Management Co.....	1.0%
Morgan Stanley Smith Barney LLC	1.0%
<i>Mutual Fund</i>	<i>Holding %</i>
Bascom Hill Partners LLC	2.2%
First Eagle Investment Management LLC	1.5%
BlackRock Fund Advisors	1.3%
ING Investment Management Co.....	1.0%
Morgan Stanley Smith Barney LLC	1.0%

Source: Thomson Reuters